A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.

@article{Brereton2010ACA,
  title={A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.},
  author={Nic Brereton and Keith Bodger and M. Kamm and Paul S. Hodgkins and Songkai Yan and Ron L. Akehurst},
  journal={Journal of medical economics},
  year={2010},
  volume={13 1},
  pages={148-61}
}
OBJECTIVES To perform a cost-utility analysis of a new formulation of mesalazine (Mezavant XL, MMX mesalazine) versus an existing oral mesalazine (Asacol; mesalazine) from the UK National Health Service perspective. METHODS A 5-year Markov cohort model was developed. Costs were obtained from the literature and utilities from an independent study. Uncertainty was evaluated using one-way and probabilistic sensitivity analyses (PSA). The potential effect of dosing frequency on adherence and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Twelve-month persistence with 5-aminosalicylic acid therapy: results from a large pharmacy database

  • SV Kane, M Sumner, D Solomon
  • 2009
1 Excerpt

Satisfaction with healthcare in inflammatory bowel disease: influence of patient characteristics. Gut 2007;56(Suppl 2):A145 (Abstract

  • C Luces, E Brown, K. Bodger
  • 2007

Similar Papers

Loading similar papers…